drugset / Trial / NCT04154774
A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) of apalutamide in participants with severe hepatic impairment relative to participants with normal hepatic function.
Timeline
- Start
- 2019-11-07
- Primary completion
- 2025-02-10
- Completion
- 2025-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apalutamide | Small molecule | — | Oral |
Indications
No indication recorded.